You are about to leave the website of Otsuka Novel Products GmbH and view the content of an external website. Otsuka Novel Products GmbH cannot be held responsible for the content of external websites.
Otsuka began its drug discovery programme in Tokushima, Japan, in 1971 with only 14 scientists. Tuberculosis (TB) was selected as one of the company’s first research priorities. Seeing the real suffering TB continued to cause in Asia, and driven by the personal commitment of Mr. Akihiko Otsuka to find new tools against this persisting epidemic, Otsuka continued to search for innovative solutions at a time when most pharmaceutical companies were closing their TB research and development (R&D) programmes.
We’ve come a long way in the last 50 years. In 2014, a compound discovered and developed by in-house scientists received its first stringent regulatory approval for the treatment of adults with pulmonary multidrug-resistant TB (MDR-TB). Today, Otsuka’s Global TB Programme is involved in initiatives around the world and has an active R&D portfolio of new medicines, child-friendly formulations, mHealth projects, TB diagnostics, and treatment monitoring tools.
Otsuka’s strategy for fighting TB is reflected in its FighTBack initiative, which encompasses 4 pillars: 1. Innovative R&D 2. Responsible access to medicines 3. Research and global health collaboration 4. Curbing drug resistance We invite you to learn more about each of the pillars by clicking on the boxes below:
TB elimination necessitates mutually reinforcing strategies that put the patient at the centre of its efforts, providing them with optimised and shortened treatment, support necessary to complete it, and ensuring that these treatment options remain viable through a commitment to antimicrobial stewardship. Partnerships and collaborations are essential to ensure antimicrobial stewardship of TB medications and to continue R&D into more effective ways to fight the disease.
Information current as of 26-10-2022Reference ONP-COP-2200002